Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 16/20 | 0.66 |
| ▸ | VEGFA | P15692 | 11/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ARNT | P27540 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20182727 | 0.90 | EPAS1 (0.65) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL19872298 | 0.90 | EPAS1 (0.65) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL18670810 | 0.88 | VEGFA (0.66) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL18068129 | 0.88 | VEGFA (0.66) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL20182725 | 0.86 | EPAS1 (0.66) | EPAS1VEGFA | |
| SCHEMBL16560911 | 0.79 | EPAS1 (1.00) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL16560907 | 0.79 | EPAS1 (1.00) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL16560855 | 0.79 | EPAS1 (1.00) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL29426414 | 0.79 | EPAS1 (1.00) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL21432387 | 0.79 | VEGFA (0.47) | EPAS1VEGFACYP2C9ARNTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | EPAS1 15/4885VEGFA 89/4885CYP2C9 4578/4885 |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | EPAS1 15/4885VEGFA 89/4885CYP2C9 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.